Login to Your Account

Exelixis' cobimetinib ups overall survival benefit with Zelboraf

By Michael Fitzhugh
Staff Writer

Tuesday, October 6, 2015

Exelixis Inc.'s MEK-inhibitor cobimetinib, given in combination with Roche AG's Zelboraf, significantly improved OS vs. Zelboraf alone for previously untreated patients with unresectable locally advanced or metastatic melanoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription